Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 3864
  • Home
  • Print this page
  • Email this page

   Table of Contents      
BRIEF REPORT
Year : 2006  |  Volume : 54  |  Issue : 4  |  Page : 278-280

The treatment of ocular tuberculosis: A survey of published literature


Lilavati Hospital and Research Centre, Mumbai, India

Correspondence Address:
Salil Mehta
202, Laxmi Villa, M.G.Road, Kandivali (W), Mumbai - 400 067
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.27959

Rights and Permissions
  Abstract 

With an expanding awareness of ocular tuberculosis, ophthalmologists are increasingly required to participate in the care of these patients. We conducted a survey of published ophthalmic literature to identify whether the regimens of antitubercular medications prescribed conform to current guidelines. A Medline search for publications (1995-2005) was done and the data were systematically analyzed with respect to demographic features, clinical findings and the antitubercular therapy prescribed. Of the 34 papers (82 patients) available, 33 papers described the prescribed antitubercular therapy. Eighteen papers (54.5%, 46 patients) conformed to guidelines versus 15 papers (45.4%, 32 patients) did not, suggesting that a large proportion of papers do not conform to current guidelines. Wider dissemination of therapeutic guidelines is necessary to encourage rational therapy and minimize therapeutic failures, drug resistance or relapse.

Keywords: Antitubercular agents, ocular tuberculosis, survey


How to cite this article:
Mehta S. The treatment of ocular tuberculosis: A survey of published literature. Indian J Ophthalmol 2006;54:278-80

How to cite this URL:
Mehta S. The treatment of ocular tuberculosis: A survey of published literature. Indian J Ophthalmol [serial online] 2006 [cited 2019 Nov 15];54:278-80. Available from: http://www.ijo.in/text.asp?2006/54/4/278/27959

Table 2: The various reported clinical findings of 82 patients of ocular tuberculosis

Click here to view
Table 2: The various reported clinical findings of 82 patients of ocular tuberculosis

Click here to view
Table 1: The levels of evidence for the diagnosis of ocular tuberculosis

Click here to view
Table 1: The levels of evidence for the diagnosis of ocular tuberculosis

Click here to view
An increasing awareness of ocular tuberculosis, often associated with systemic infection, requires ophthalmologists to be aware of and prescribe rational therapy to achieve optimal outcomes. Current literature describes numerous therapeutic regimens differing in the number of drugs prescribed,[1] dosages and duration of treatment.[2] As this primary literature is an important source of therapeutic information, we analyzed these to identify antitubercular prescribing patterns and compared them to current recommendations.


  Materials and Methods Top


We conducted a Medline search using the search terms "ocular tuberculosis, intraocular tuberculosis and choroidal tuberculosis". We identified publications from January 1995 to May 2005 and excluded reviews, papers that focused on diagnosis, publications in any language except English or Spanish and orbital/adnexal tuberculosis. A total of 34 papers described the diagnosis and treatment of single or multiple patients and we analyzed these.

The following data were extracted: number of cases, age and sex, country of origin of the patients (if specified, otherwise it was taken to be the country of origin of the paper), ocular findings, the presence or absence of systemic tuberculosis, basis of diagnosis [Table - 1] and the antitubercular therapy given (drugs, dosages and duration of therapy).


  Results Top


In the 34 papers analyzed,[1],[2],[3],[4],[5],[6],[7],[8],[9],[10],[11],[12],[13],[14],[15],[16],[17],[18],[19],[20],[21],[22],[23],[24],[25],[26],[27],[28],[29],[30],[31],[32],[33],[34] a total of 82 patients (52 males and 30 females) were described with ages ranging from 8 years to 70 years (mean 36). The majority were from India (46, 56.0%) followed by Japan (10, 12.1%). Other nationalities included patients from Malawi, Spain, the US (four each, 4.8%), Taiwan (three, 3.6%), Turkey, Mexico (two each, 2.4%), Ecuador, Brazil, Pakistan, South Korea, Sierra Leone, France and Guinea (one each, 1.2%). The described ocular manifestations are enumerated in [Table - 2].

A variety of diagnostic methods were used to diagnose intraocular tuberculosis. These included analysis of aqueous fluid in the form of smear for acid-fast bacilli, culture and polymerase chain reaction (PCR). The study of vitreous specimens or eyeball histopathology have been done in few cases. Systemic investigations included chest X-rays/computed tomography (CT) scans, bronchoscopy and Mantoux tests. Additionally, diagnosis was obtained from the culture/PCR/histopathology of sputum, lymph nodes or organ systems. The levels of evidence for the diagnosis included 36 (43.90%) patients with Level I, 16 (19.5%) with Level II and 30 (36.5%) with Level III evidence. In 31 papers (77 patients) the presence of systemic tuberculosis (usually pulmonary) was clinically suspected or proven whereas three papers described five patients with no evidence of systemic tuberculosis.[19],[21],[32] A total of six (17.6%) papers identified 12 patients with human immunodeficiency virus (HIV) infection/acquired immune deficiency syndrome (AIDS).

As no recent randomized trials have been conducted to assess the optimum treatment for patients with ocular tuberculosis, we have used for discussion, the recommendations described for treatment of pulmonary and extrapulmonary tuberculosis, even though intraocular inflammation was not specifically described.

The American Thoracic Society (ATS), the Centres for Disease Control (CDC) and the Infectious Diseases Society of America (IDSA) have recommended four drugs [isoniazid (INH), pyrazinamide (PZA), ethambutol (EMB) and rifampicin (RIF)] for an initial eight weeks followed by INH and RIF either seven days a week (Regimen 1a) or twice weekly (Regimen 1b) for a minimum duration of 18 weeks.[35] The efficacy and effectiveness of these regimens has led to a rating of A 1 (A = preferred regimen; 1 = based on randomized clinical trials) and A 2 (A = preferred regimen; 2 = based on nonrandomized clinical trials) for HIV negative and positive patients respectively. These principles also apply to extrapulmonary forms of the disease or HIV-infected patients, with evidence suggesting that similar regimens of four drugs for a period of 6-9 months are effective.

The World Health Organization recommendations also require the use of four drugs (INH/RIF/PZA/ETB) for an initial two months followed by INH/RIF for four months for Category I patients (new sputum positive patients, new sputum negative patients with extensive lung parenchymal disease and those with severe extrapulmonary disease) as well patients in Category III (new smear negative patients with lesser lung parenchymal involvement and patients with less severe extrapulmonary disease).[36]

Thirty-three papers (78 patients) described the antitubercular therapy in sufficient detail and this was compared to these recommendations. The therapy in 18 papers (54.5%, 46 patients) conformed to guidelines whereas those in 15 (45.4%, 32 patients) did not.


  Discussion Top


The aims of chemotherapy include the rapid killing of bacilli, reducing the risk of drug resistance and preventing relapse by eliminating residual bacilli. To achieve this, multiple drugs are prescribed for an adequate duration. Theoretical models describe three distinct subpopulations of bacilli. The largest subpopulation consists of fast multipliers located within cavities. INH (followed by EMB, RIF and PZA) is the most effective in killing these bacilli and reduces the risk of resistance developing within the bacillary population. The other more slowly growing bacilli subpopulations are responsible for relapses and treatment failures and need to be treated with drugs that possess a potent sterilizing ability (RIF/PZA).

All of the patients underwent clinical examination, chest X-ray and/or chest CT scan and Mantoux test to detect systemic tuberculosis with pulmonary tuberculosis being detected in the majority. Intraocular tuberculosis was suspected clinically and confirmed using smears, culture, PCR or histopathology of fluids/tissue. HIV/AIDS was frequently found in these patients and is a known risk factor.

While the majority of the reports were in accordance with recommendations, a significant proportion of the papers had regimens that are nonguideline-based. Common deviations included an inadequate number of drugs (varying from one to three) or an inadequate duration of treatment (often as little as two to three months). Only one group of authors provided a rationale for nonguideline-based therapy by highlighting a low incidence of resistance to INH and RIF (1.1 to 1.7% and 0.5 to 0.7% respectively) in their home country (Japan).[12] In our opinion, the low incidence of drug resistance should encourage the use of combination drug therapy designed to prevent its occurrence. One report described the use of rifabutin in place of RIF in an HIV positive patient that is rationally correct and overcomes deleterious RIF-antiretroviral interactions.[29]

Nonguideline-based regimens carry the risk of inadequate treatment; increase the risk of subsequent drug resistance and relapse for both the systemic and the ocular infections. Wider dissemination of this fact will enable ophthalmologists to prescribe rational therapy.



 
  References Top

1.
Tayanc E, Akova Y, Yilmaz G. Indocyanine green angiography in ocular tuberculosis. Ocul Immunol Inflamm 2004;12:317-22.  Back to cited text no. 1
[PUBMED]  [FULLTEXT]  
2.
Morimura Y, Okada AA, Kawahara S, Miyamoto Y, Kawai S, Hirakata A, et al . Tuberculin skin testing in uveitis patients and treatment of presumed intraocular tuberculosis in Japan. Ophthalmology 2002;109:851-7.  Back to cited text no. 2
    
3.
Mehta S, Gilada IS. Ocular tuberculosis in acquired immune deficiency syndrome (AIDS). Ocul Immunol Inflamm 2005;13:87-9.  Back to cited text no. 3
    
4.
Cassoux N, Charlotte F, Rao NA, Bodaghi B, Merle-Beral H, Lehoang P. Endoretinal biopsy in establishing the diagnosis of uveitis: A clinicopathologic report of three cases. Ocul Immunol Inflamm 2005;13:79-83.  Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.
Mehta S. Ocular lesions in acute disseminated tuberculosis. Ocul Immunol Inflamm 2004;12:311-5.  Back to cited text no. 5
[PUBMED]  [FULLTEXT]  
6.
Chawla R, Garg S, Venkatesh P, Kashyap S, Tewari HK. Case report of tuberculous panophthalmitis. Med Sci Monit 2004;10:CS57-9.  Back to cited text no. 6
[PUBMED]  [FULLTEXT]  
7.
Romero Aroca P, Castro Salomo A, Martinez Salcedo I, Almena Garcia M, Salvat Serra M, Zamora Barrios J. Tuberculous retinitis with associated periphlebitis. Arch Soc Esp Oftalmol 2004;79:81-4.   Back to cited text no. 7
[PUBMED]  [FULLTEXT]  
8.
Gupta A, Gupta V, Pandav SS, Gupta A. Posterior scleritis associated with systemic tuberculosis. Indian J Ophthalmol 2003;51:347-9.  Back to cited text no. 8
    
9.
Salman A, Parmar P, Rajamohan M, Thomas PA, Jesudasan N. Subretinal fluid analysis in the diagnosis of choroidal tuberculosis. Retina 2003;23:796-9.  Back to cited text no. 9
[PUBMED]  [FULLTEXT]  
10.
Gupta V, Gupta A, Arora S, Bambery P, Dogra MR, Agarwal A. Presumed tubercular serpiginouslike choroiditis: Clinical presentations and management. Ophthalmology 2003;110:1744-9.   Back to cited text no. 10
[PUBMED]    
11.
Sharma PM, Singh RP, Kumar A, Prakash G, Mathur MB, Malik P. Choroidal tuberculoma in miliary tuberculosis. Retina 2003;23:101-4.  Back to cited text no. 11
[PUBMED]  [FULLTEXT]  
12.
Gopal L, Rao SK, Biswas J, Madhavan HN, Agarwal S. Tuberculous granuloma managed by full thickness eye wall resection. Am J Ophthalmol 2003;135:93-4.  Back to cited text no. 12
[PUBMED]  [FULLTEXT]  
13.
Gupta A, Gupta V, Arora S, Dogra MR, Bambery P. PCR-positive tubercular retinal vasculitis: Clinical characteristics and management. Retina 2001;21:435-44.  Back to cited text no. 13
[PUBMED]  [FULLTEXT]  
14.
Sheu SJ, Shyu JS, Chen LM, Chen YY, Chirn SC, Wang JS. Ocular manifestations of tuberculosis. Ophthalmology 2001;108:1580-5.  Back to cited text no. 14
[PUBMED]  [FULLTEXT]  
15.
Brice SE, Oldfield MD, Barker R. Stridor, malaise and visual loss in a woman from Sierra Leone. Postgrad Med J 2001;77:601,607-8.  Back to cited text no. 15
[PUBMED]  [FULLTEXT]  
16.
Fernandez CC, Garcia JJ, Moro BD, Blanco JA, Suarez ML. Choroidal tubercles in miliary tuberculosis. Arch Soc Esp Oftalmol 2000;75:355-8.  Back to cited text no. 16
[PUBMED]  [FULLTEXT]  
17.
Raina UK, Tuli D, Arora R, Mehta DK, Taneja M. Tubercular endophthalmitis simulating retinoblastoma. Am J Ophthalmol 2000;130:843-5.  Back to cited text no. 17
[PUBMED]  [FULLTEXT]  
18.
Mason JO. Treatment of large macular choroidal tubercle improves vision. Arch Ophthalmol 2000;118:1136-7.  Back to cited text no. 18
[PUBMED]  [FULLTEXT]  
19.
Sarvanathan N, Wiselka M, Bibby K. Intraocular tuberculosis without detectable systemic infection. Arch Ophthalmol 1998;116:1386-8.  Back to cited text no. 19
    
20.
Grewal A, Kim RY, Cunningham ET Jr. Miliary tuberculosis. Arch Ophthalmol 1998;116:953-4.  Back to cited text no. 20
[PUBMED]  [FULLTEXT]  
21.
Berinstein DM, Gentile RC, McCormick SA, Walsh JB. Primary choroidal tuberculoma. Arch Ophthalmol 1997;115:430-1.  Back to cited text no. 21
[PUBMED]    
22.
Muccioli C, Belfort R Jr. Presumed ocular and central nervous system tuberculosis in a patient with the acquired immunodeficiency syndrome. Am J Ophthalmol 1996;121:217-9.  Back to cited text no. 22
[PUBMED]    
23.
Biswas J, Madhavan HN, Gopal L, Badrinath SS. Intraocular tuberculosis. Clinicopathologic study of five cases. Retina 1995;15:461-8.  Back to cited text no. 23
[PUBMED]    
24.
Mehta S. Role of computed chest Tomography (CT scan) in tuberculous retinal vasculitis. Ocul Immunol Inflamm 2002;10:151-5.  Back to cited text no. 24
[PUBMED]    
25.
Beare NA, Kublin JG, Lewis DK, Schijffelen MJ, Peters RP, Joaki G, et al . Ocular disease in patients with tuberculosis and HIV presenting with fever in Africa. Br J Ophthalmol 2002;86:1076-9.  Back to cited text no. 25
    
26.
Han BG, Choi SO, Lee SJ, Kim YH, Hong WP, Lee JH. Choroidal tuberculoma with membranous glomerulonephritis. Yonsei Med J 2001;42:446-50.   Back to cited text no. 26
[PUBMED]  [FULLTEXT]  
27.
Juan J, Ruiz MA, Arnedo L, Ramos JA, Tornero C. Fever and skin lesion in 70 year old men with Hodgkin's lymphoma. Enferm Infecc Microbiol Clin 2001;19:181-2.  Back to cited text no. 27
[PUBMED]  [FULLTEXT]  
28.
Recillas-Gispert C ortega-Larrocea G, Arellanes-Garcia L, Herrera-Barrios T, Sada-Diaz E. Chorioretinitis secondary to mycobacterium tuberculosis in acquired immune deficiency syndrome. Retina 1997;17:437-9.  Back to cited text no. 28
    
29.
DiLoreto DA Jr, Rao NA. Solitary nonreactive choroidal tuberculoma in a patient with acquired immune deficiency syndrome. Am J Ophthalmol 2001;131:138-40.  Back to cited text no. 29
    
30.
Rathinam SR, Rao NA. Tuberculous intraocular infection presenting with pigmented hypopyon: A clinicopathological case report. Br J Ophthalmol 2004;88:721-2.  Back to cited text no. 30
    
31.
Perez Alvarez MJ, Gonzalez Guijarro J, Santos Gil I. Tuberculous peripheral multifocal choroiditis. Arch Soc Esp Oftalmol 2003;78:169-72.  Back to cited text no. 31
    
32.
Levecq LL, De Potter P. Solitary choroidal tuberculoma in an immunocompetent patient. Arch Ophthalmol 2005;123:864-6.  Back to cited text no. 32
    
33.
Reny JL, Challe G, Geisert P, Aris J, Ziza J, Ragais G. Tuberculosis-related retinal vasculitis in an immunocompetent patient. Clin Infect Dis 1996;22:873-4.  Back to cited text no. 33
    
34.
Torres RM, Calonge M. Macular edema as the only ocular finding of tuberculosis. Am J Ophthalmol 2004;138:1048-9.  Back to cited text no. 34
    
35.
American Thoracic Society, CDC and Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003;52:1-77.  Back to cited text no. 35
    
36.
World Health Organization. Treatment of Tuberculosis. Guidelines for National Programmes (WHO/CDS/TB/2003.313). Available online at www.who.int/entity/tb/publications/cds_tb_2003_313. Accessed 06 June 05.  Back to cited text no. 36
    



 
 
    Tables

  [Table - 1], [Table - 2]


This article has been cited by
1 Clinical spectrum of tuberculous optic neuropathy
Journal of Ophthalmic Inflammation and Infection. 2012;
[VIEW] | [DOI]
2 Intraocular tuberculosis
Reema Bansal,Aman Sharma,Amod Gupta
Expert Review of Ophthalmology. 2012; 7(4): 341
[Pubmed] | [DOI]
3 The Use of the QuantiFERON-Tuberculosis Gold Test in the Diagnosis of Ocular Tuberculosis
Yasemin Ozdamar, Seyhan S. Ozkan, Emrullah Beyazyildiz, Pinar Cakar Ozdal, Kuddusi Teberik, Aysegul Kocak Altintas
Journal of Pediatric Ophthalmology & Strabismus. 2010;
[VIEW] | [DOI]
4 Waxing-waning visual symptoms: Masquerading multiple sclerosis and delaying the diagnosis of concomitant ocular and cerebral tuberculosis
Baisakhiya, S., Agrawal, A., Cincu, R.
Infectious Diseases in Clinical Practice. 2010; 18(2): 124-127
[Pubmed]
5 Ocular tuberculosis: an update
Sudharshan Sridharan, Jyotirmay Biswas
Expert Review of Ophthalmology. 2007; 2(5): 845
[VIEW] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
Abstract
Materials and Me...
Results
Discussion
References
Article Tables

 Article Access Statistics
    Viewed6966    
    Printed127    
    Emailed9    
    PDF Downloaded745    
    Comments [Add]    
    Cited by others 5    

Recommend this journal